Kevin Feeley Sells 1,285 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,285 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $108,222.70. Following the completion of the transaction, the chief financial officer directly owned 41,476 shares in the company, valued at approximately $3,493,108.72. The trade was a 3.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, June 16th, Kevin Feeley sold 3,729 shares of GeneDx stock. The stock was sold at an average price of $60.77, for a total value of $226,611.33.

GeneDx Stock Up 1.3%

Shares of GeneDx stock traded up $1.06 on Friday, hitting $85.02. The company had a trading volume of 331,592 shares, compared to its average volume of 938,779. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30. The stock has a 50 day moving average of $74.31 and a 200-day moving average of $66.65. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -23.36 and a beta of 1.99.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, August 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.20. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%.The company had revenue of $114.44 million for the quarter, compared to analysts’ expectations of $111.01 million. During the same quarter in the previous year, the firm earned $0.36 earnings per share. As a group, sell-side analysts forecast that GeneDx Holdings Corp. will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC grew its position in shares of GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after purchasing an additional 142 shares in the last quarter. Main Management ETF Advisors LLC lifted its holdings in GeneDx by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after purchasing an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after purchasing an additional 181 shares during the period. Strs Ohio boosted its stake in GeneDx by 8.7% in the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after purchasing an additional 200 shares during the period. Finally, Kestra Advisory Services LLC purchased a new position in GeneDx during the 4th quarter valued at about $27,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

WGS has been the subject of several recent analyst reports. Guggenheim reiterated a “buy” rating and issued a $74.00 target price (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Canaccord Genuity Group boosted their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 26th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $89.57.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.